Success Story: I-140 NIW Approval for a Molecular Biology Researcher from China with Our Expert Filing
Client’s Testimonial:
"Thank you again for all your help and support throughout my NIW application process.”
On March 9th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a PhD candidate in the Field of Molecular Biology (Approval Notice).
General Field: Molecular Biology
Position at the Time of Case Filing: PhD candidate
Country of Origin: China
Country at the Time of Filing: Canada
Approval Notice Date: March 9th, 2026
Processing Time: 8 months, 17 days (Premium Processing Upgrade Requested)
Case Summary:
The client’s I-140 NIW approval reflects a petition that clearly tied her research to pressing medical needs in the United States. With an M.S. in internal medicine, the client was presented as an expert in molecular biology whose proposed endeavor is to continue investigating the molecular mechanisms of genetic diseases, particularly neurodegenerative and neuromuscular disorders such as Huntington’s disease, myotonic dystrophy type 1, and ALS, in order to develop targeted therapeutic strategies that address their underlying causes. The petition framed this work as having both substantial merit and national importance because it supports precision medicine, addresses serious public health burdens, and contributes to better long-term treatment outcomes.
Rather than relying on credentials alone, the case showed that the client was well-positioned to advance this endeavor through a combination of training, prior results, and a focused future research plan. The petition emphasized her background in malignant blood diseases, the bone marrow microenvironment, drug screening, molecular and cellular biology, bioinformatics, and transcriptomic data interpretation. It also described her planned continued work on small molecules and repeat-expansion disorders, showing an adjudicator not just what she had done already, but why her prior work made her a credible candidate to keep contributing in this area.
Her publication record was presented in a way that highlighted quality and relevance. The client had authored 7 peer-reviewed journal articles, including 2 first-authored papers, along with 3 abstracts, including 1 first-authored abstract. The petition did not treat those numbers as automatically persuasive. Instead, it explained that her work appeared in highly regarded journals, which helped show that her findings had passed meaningful scrutiny and were considered valuable by the field.
The citation evidence was also framed strategically. The client’s published work had received 135 citations, but the stronger point was how those citations compared with field norms. The petition showed that 3 of her papers ranked among the top 10% most cited for their publication years, and another ranked among the top 20% in Molecular Biology and Genetics. That kind of percentile analysis gives an adjudicator a more reliable way to assess influence than a raw total alone because it shows independent reliance on the client’s research across time-adjusted field standards.
Most importantly, the petition demonstrated significance through the substance of the client’s work. It highlighted contributions involving platelet production, bone marrow endothelial repair, and vascular protection after chemotherapy and irradiation, then connected those findings to the broader goal of developing therapies for serious genetic and degenerative diseases. In that way, the approval was supported not simply by publications and citations, but by a persuasive showing that the client’s research has already informed other scientists and is positioned to continue generating nationally important medical advances.